NCT03732664View on ClinicalTrials.gov

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

March 23, 2023

Study Completion Date

March 23, 2023

Conditions
High-Risk Resectable NSCLC
Interventions
DRUG

Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab

One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.

Trial Locations (1)

310009

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT03732664 - ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter